Olr34 inhibitors represent a class of chemical compounds that specifically interact with the Olr34 receptor, a member of the olfactory receptor family. Olfactory receptors, typically known for their role in the detection of odorants in the nasal epithelium, are G protein-coupled receptors (GPCRs) with seven transmembrane domains. These receptors can be expressed in various tissues beyond the olfactory system, where they may play a role in diverse signaling pathways. The inhibition of Olr34 can influence signal transduction by blocking the interaction between the receptor and its endogenous ligands. This interaction typically involves the binding of small molecules or peptides to the receptor's active site, leading to the activation or suppression of downstream signaling cascades. Inhibitors of Olr34 are characterized by their ability to modulate this receptor's activity, often through competitive or allosteric mechanisms, thereby altering the receptor's conformational state and subsequent cellular responses.
Chemically, Olr34 inhibitors can vary in structure, ranging from small organic molecules to larger peptide-based inhibitors. The design of these inhibitors often involves the optimization of molecular features such as hydrophobicity, charge distribution, and spatial orientation to enhance binding affinity and specificity for the Olr34 receptor. Structural studies, including X-ray crystallography and molecular docking simulations, have provided insights into the receptor's binding pocket, enabling the rational design of inhibitors that can effectively target the receptor. Moreover, the study of Olr34 inhibitors can involve various in vitro and in vivo assays to assess their binding kinetics, receptor affinity, and the resultant changes in signal transduction pathways. This detailed understanding of Olr34 inhibition mechanisms opens new avenues for exploring the broader implications of olfactory receptor modulation in non-olfactory tissues and their involvement in complex physiological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Sodium channel blocker, can indirectly affect GPCR signaling by altering ionic balance, potentially impacting Olr34. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may disrupt GPCR signaling pathways, influencing Olr34. | ||||||
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $49.00 $91.00 | 21 | |
ACE inhibitor, could indirectly modulate GPCR signaling related to angiotensin II, impacting Olr34. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Adrenergic receptor agonist, could modulate GPCR signaling, potentially impacting Olr34. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Loop diuretic, can indirectly affect GPCR signaling through altered kidney function and electrolyte balance, impacting Olr34. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Sodium channel blocker, might influence GPCR signaling indirectly by affecting nerve conduction, impacting Olr34. | ||||||
L-Noradrenaline | 51-41-2 | sc-357366 sc-357366A | 1 g 5 g | $326.00 $485.00 | 3 | |
Adrenergic receptor agonist, could alter GPCR signaling pathways, potentially affecting Olr34. | ||||||
Oxybutynin | 5633-20-5 | sc-489869 | 1 g | $135.00 | ||
Antimuscarinic, can modulate GPCR signaling, potentially affecting Olr34. | ||||||
Scopolamine | 51-34-3 | sc-473216 sc-473216A sc-473216B | 100 mg 500 mg 1 g | $172.00 $506.00 $786.00 | 2 | |
Muscarinic antagonist, could modulate GPCR signaling, impacting Olr34. | ||||||